Antibody-drug conjugate target selection: critical factors.
about
Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)Antibody Drug Conjugates: Preclinical ConsiderationsMicrotubule inhibitor-based antibody-drug conjugates for cancer therapy.The development of potential antibody-based therapies for myelomaReceptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes.Computational selection of antibody-drug conjugate targets for breast cancer.Antibody-drug conjugates: Intellectual property considerations.The delivery of therapeutic oligonucleotidesMethods for site-specific drug conjugation to antibodies.Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.Antibody-mediated delivery of therapeutics for cancer therapy.Prospects and progress of antibody-drug conjugates in solid tumor therapies.Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.Evolving Strategies for Target Selection for Antibody-Drug Conjugates.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killingProtease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds
P2860
Q26768654-C8764EC3-5EEB-47AF-883D-2865E81472E8Q27022321-2115E344-182C-4E28-8EAA-70F3F964273DQ34655256-DE610F56-E261-489D-B255-2533C882B612Q35788245-7A4D22A9-766A-434C-AA4D-8BA7764576E0Q36427101-FBC34A0E-978B-436D-BF45-FA4157352105Q36771856-85396D94-59D0-4954-87D8-BA74E3178439Q37138213-C3A1B586-ED3B-4849-BCC0-9E4FBFD369FDQ37210936-B1D44605-F141-403A-9E23-15557E253D08Q37593707-70F4F044-BD5B-4C6E-8F8F-155D3A167D35Q37606966-D32E161B-0E02-44E5-9CF5-6CC5361E71B4Q38665425-AF6B5A89-4736-46BE-A60A-54E2E0EA99EBQ38798525-869A00E8-AAD4-4BC1-A266-0E9723544A0EQ38842103-320C29FA-66C5-42AE-A909-409DF2C9AF51Q38920359-541CF841-26BF-4A99-BD42-0FC9FDAC6DD7Q41282870-F6356FFF-BD9D-4387-B180-5F42EC083C82Q41512417-F65A51D1-17C1-4032-909E-3941CE23B58BQ48199774-8C501F5B-F290-41E5-89A5-2FB050C82BB4Q58869554-7ED1D48C-D9FB-4B1A-968E-DFE50F2B242E
P2860
Antibody-drug conjugate target selection: critical factors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antibody-drug conjugate target selection: critical factors.
@en
type
label
Antibody-drug conjugate target selection: critical factors.
@en
prefLabel
Antibody-drug conjugate target selection: critical factors.
@en
P1476
Antibody-drug conjugate target selection: critical factors.
@en
P2093
Neil H Bander
P356
10.1007/978-1-62703-541-5_2
P407
P577
2013-01-01T00:00:00Z